跳至主要内容
临床试验/IRCT20140818018842N31
IRCT20140818018842N31招募中2 期

Assessment of the Efficacy of High-Dose Intravenous Vitamin C on Severity of Acute Graft Versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Randomized, Triple-Blind, Placebo-Control Trial

Research Institute for Oncology, Hematology and Cell Therapy0 个研究点目标入组 260 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
260

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Allogeneic hematopoietic stem cells transplantation due to any of the following hematological malignancies: Acute lymphoblastic leukemia (ALL)/ Acute myelogenous leukemia (AML)/ Myelodysplasia (MDS)/ Hodgkin's lymphoma (HL)/ non-Hodgkin's lymphoma (NHL)
  • Patient age = 18
  • Patients must also receive a full myeloablative conditioning regimen
  • HLA-full-matched stem cell donor, either related or unrelated from peripheral blood stem cell or bone marrow
  • Estimated creatinine clearance =60 ml/min
  • Serum total bilirubin = 2 x upper limit of normal value (ULN) and AST and ALT = 2 x ULN
  • Karnofsky Performance Status of 60-100% or Eastern Cooperative Oncology Group (ECOG) performance status =2
  • Ability to understand and the willingness to sign a written informed consent document

排除标准

  • Known allergy to vitamin C
  • G6PDH deficiency
  • Patients with hemochromatosis
  • History of kidney stones or oxaluria during the last 5 years
  • Uncontrolled viral, fungal, or bacterial infection
  • Allogeneic or autologous hematopoietic stem cells transplantation in the past 12 monthsPregnancy or breastfeeding
  • Left ventricular ejection fraction < 40%
  • Patient participation in another similar research project simultaneously
  • Pregnancy or breastfeeding

研究者

发起方
Research Institute for Oncology, Hematology and Cell Therapy

相似试验